Bloomberg Quicktake: Now published this video item, entitled “Merck’s Covid-19 Pill Reduces Hospitalizations, Deaths by 50%: Trials” – below is their description.
Merck & Co. shares posted their biggest gain in 12 years after the company’s experimental pill slashed the risk of getting seriously ill or dying from Covid-19 in a study, findings that could eventually yield a simple way to treat many virus patients before they ever reach the hospital.
The drug, known as molnupiravir, reduced the risk of hospitalization or death by 50% in an interim analysis of a late-stage clinical trial, Merck and partner Ridgeback Biotherapeutics LP said in a statement on Friday.
The study results were so encouraging that Merck and closely held Ridgeback, in consultation with independent trial monitors and the U.S. Food and Drug Administration, elected to stop enrolling patients and begin the process of gaining regulatory clearance.
“We couldn’t be more thrilled with the results,” Merck Chief Executive Officer Rob Davis said in an interview. “You don’t have to go to the hospital, you don’t have to go to a center to have it infused. It’s a pill you can take at home.”Bloomberg Quicktake: Now YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.